Cargando…
Therapeutic Vaccines for Genitourinary Malignancies
The field of genitourinary malignancies has been a showcase for therapeutic cancer vaccine success since the application of intravesicular Bacillus Calmette-Guerin (BCG) for bladder cancer in the 1970s and enjoyed a renaissance in 2010 with the US Food and Drug Administration (FDA) approval of sipul...
Autores principales: | Dutcher, Giselle M. A., Bilen, Mehmet Asim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161030/ https://www.ncbi.nlm.nih.gov/pubmed/30103542 http://dx.doi.org/10.3390/vaccines6030055 |
Ejemplares similares
-
Immunotherapy in genitourinary malignancies
por: Mehta, Kathan, et al.
Publicado: (2017) -
Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021) -
Immunotherapy of Genitourinary Malignancies
por: Inamoto, Teruo, et al.
Publicado: (2012) -
The human microbiome and genitourinary malignancies
por: Nicolaro, Michael, et al.
Publicado: (2020) -
Emerging therapeutic agents for genitourinary cancers
por: Zarrabi, Kevin, et al.
Publicado: (2019)